{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-286880","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-06-29T12:05:06+00:00","discovered_at":"2026-06-29T12:10:00.300162+00:00","generated_at":"2026-06-29T12:10:18.498926+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"4D Molecular Therapeutics secures up to $200M term loan facility with Hercules Capital","bullets":["Initial $20M drawn at closing; additional tranches available up to $200M total, maturing June 1, 2031.","Interest rate: prime + 2.00% (min 8.75%) for Tranche 1A; other tranches prime + 2.50% (min 9.25%).","Covenants include minimum cash test when borrowings exceed $25M or $50M; performance covenant tied to FDA approval and revenue.","Loans secured by substantially all assets including intellectual property; future subsidiaries may guarantee obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-286880","json":"https://secwatch.observer/filing/0001193125-26-286880.json","markdown":"https://secwatch.observer/filing/0001193125-26-286880.md","text":"https://secwatch.observer/filing/0001193125-26-286880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/0001193125-26-286880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/d146057d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:10:18.498926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}